Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy
- PMID: 30472869
- DOI: 10.4149/av_2018_407
Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy
Abstract
Oncolytic virotherapy offers the potential to treat tumors both as a single agent and in combination with conventional therapies such as chemotherapy and immunological therapy. Here, we describe an effective treatment regimen which combines virotherapy with immunotherapy. IFN-α and co-stimulator IL-2 along with tumor cell lysate vaccination with intratumoral administration of oncolytic vesicular stomatitis virus (VSV) resulted in regression of established TC1 papilloma tumor model in C57BL/6 mice. The remarkable results especially in the group receiving tumor vaccination and virotherapy together (TC1-VSV) were obtained. Combination therapy synergistically enhanced CTL activity against tumor cells and reduced tumor size, although significant reduction in tumor size was observed in both groups receiving VSV or tumor vaccine alone. The presented data suggest that the effectiveness of virotherapy is enhanced when combined with immunotherapy by priming specific CD8 T cells against tumor antigens through tumor vaccination and boosting by exposure of antigens upon virus infection. Keywords: virotherapy; VSV; tumor vaccine; immunotherapy; IFN-α; IL-2.
Similar articles
-
Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.Int J Cancer. 2019 Oct 1;145(7):1958-1969. doi: 10.1002/ijc.32325. Epub 2019 Apr 29. Int J Cancer. 2019. PMID: 30972741 Free PMC article.
-
Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143. Hum Gene Ther. 2010. PMID: 19922169 Free PMC article.
-
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.J Immunother Cancer. 2022 Mar;10(3):e003923. doi: 10.1136/jitc-2021-003923. J Immunother Cancer. 2022. PMID: 35246474 Free PMC article.
-
Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis Virus.DNA Cell Biol. 2024 Feb;43(2):57-60. doi: 10.1089/dna.2023.0368. Epub 2023 Dec 11. DNA Cell Biol. 2024. PMID: 38079267 Review.
-
Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.Future Oncol. 2022 Aug;18(24):2627-2638. doi: 10.2217/fon-2022-0439. Epub 2022 Jun 14. Future Oncol. 2022. PMID: 35699077 Review.
Cited by
-
Antiviral Therapeutic Potential of Curcumin: An Update.Molecules. 2021 Nov 19;26(22):6994. doi: 10.3390/molecules26226994. Molecules. 2021. PMID: 34834089 Free PMC article. Review.
-
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.Mol Ther Oncolytics. 2023 Aug 24;30:254-274. doi: 10.1016/j.omto.2023.08.010. eCollection 2023 Sep 21. Mol Ther Oncolytics. 2023. PMID: 37701850 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials